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ABSTRACT 
 
The prevalence of breast cancer is still very high among women, in particular post-menopausal women. There 
are many factors contributed to the diseases, including diabetes. Recently, it has been emerged that metformin,  
an antidiabetic agent, is capable of reducing the risk of developing breast cancer among post-menopausal 
women, and act as aromatase inhibitors (AIs) which inhibits the production of estrogen. In this review, we focus 
in discussing the possible work mechanism of metformin as AIs and what is in the pipeline on clinical trials. 
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INTRODUCTION 
Breast cancer (BC), one of the most common types of cancer in women, is primarily 
characterized by uncontrolled growth of breast epithelial cell. The global health burden of BC is very 
high among older women, particularly in post-menopausal women.1 There are around two million 
women globally affected by this disease every year, and WHO estimated that more than 600.000 
women died from breast cancer in 2018.2 Also, a meta-analysis from 126 studies in 2017 found out  
that the survival rate of a breast cancer patient is worsening within three years post-diagnosis.3 
To date, there are numerous factors involved in the development of breast cancer in women, 
including age, genetics, environment, and lifestyle.1 Diabetes is also correlated to breast cancer 
incidence and was observed by Marble et al. for the first time in the early 1930s.4 Also, several 
epidemiological studies observed that metformin, an antidiabetic drug, could significantly reduce the 
incidence and mortality rate of the breast cancer patient with type II diabetes.5-7 Furthermore, one of 
pre-clinical study in mice demonstrated that metformin can inhibit the development of breast cancer 
cells through the inhibition of stromal aromatase, which result-in blockade of estrogen production.8 
That finding opened a possibility to use metformin, an antidiabetic agent, as an adjuvant treatment for 
the breast cancer patient. Henceforth, In this article, we aim on discussing the role of metformin 
against tumorigenesis, especially as aromatase inhibitors for breast cancer. 
 
ESTROGEN, AROMATASE INHIBITOR, AND BREAST CANCER 
Estrogen is a hormone which promotes the growth and survival not only the normal cells but 
also the carcinoma cells, by binding to its receptor on the cell, estrogen receptor (ER).9 Interestingly, 
Fabian et al. found out that around 70% of breast cancers cells express a high number of ER on the   
cell surface.10 Consequently, long-exposure of estrogen during the lifetime has been identified as one  
of the main risks of breast cancer progression in women.11 There are three main ways (Figure 1) to 
disrupt the estrogen-dependent development of breast cancer cells. The first method is to prevent the 
binding of estrogen to its receptor with selective modulators such as tamoxifen. Secondly, eliminate  
the receptor expression in cells with ER down-regulator, causing less ER available for estrogen 
binding. Lastly, the most effective way is by reducing estrogen production via ovarian ablation in 
premenopausal women or using aromatase inhibitors (AIs) in menopausal women.10 
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Figure 1. Main strategies to interfere the binding of estrogen and ER. Direct inhibition of 
estrogen and ER (1), elimination of ER (2), or interfere the production of estrogen (3). 
Reproduced from Fabian et al. (2005).10 
Aromatase inhibitors are one of class drugs that is capable of disrupt estrogen conversion by 
suppressing the activities of aromatase enzyme.10 AIs play a role as adjuvant treatment for breast 
cancer, and it has been proved to prevent the recurrence of the disease.13 Of three AIs generations 
available for clinical use, the third-generation is far more superior compared to the first and second  
line AIs, due to the fact that it has minimal adverse effects. In premenopausal women, estrogen is 
synthesized and produced in ovaries, while in post-menopausal women, the production of estrogen is 
predominantly in peripheral body tissue.12 Henceforth, AIs are more effective for reducing circulating 
estrogen in post-menopausal than pre-menopausal women. 
DIABETES AND RISK OF BREAST CANCER 
Obesity and diabetes, especially type II diabetes (T2D), are known to be linked with an 
increased risk of many cancer incidences,4 including breast cancer.14 A meta-analysis study reported 
that there was a significantly higher risk of breast cancer incidence among diabetic women (SRR = 
1.13, 95% CI = 1.04, 1.24) compared to the non-diabetic women.15 Another study also observed that 
the risk of breast cancer incidence even higher in postmenopausal women with type II diabetes than 
pre-menopausal women.16 Overall, these studies implicated that there is a high correlation between 
diabetes, post-menopausal state, and breast cancer incidence in women. 
Moreover, multiple factors are contributed to a high risk of breast cancer in diabetes patients, 
particularly in T2D, including hyperinsulinemia, hyperglycaemia, and elevated insulin-like growth 
factor (IGF).17 These factors can interfere the binding of insulin and insulin receptors (IR) that mainly 
act to regulate the metabolism of glucose through phatidylinositol-3-kinase (PI3K)/Akt signalling 
pathway. It also exerts an indirect positive effect on RAS/MAPK/ERK signalling pathway which plays 
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an essential role in the cells growth, including cancerous cells.18,19 Additionally, breast cancer tissue 
also expresses more IR compared to healthy women breast tissue, hence why the cancerous epithelial 
cells can grow exponentially.20 
Surprisingly, Evans et al. (2005) found out that there is a decline in the risk of breast cancer 
among women with T2D who take metformin on a long-term basis.5 Supporting these findings, a meta-
analysis from a hundred researches around the world demonstrated that metformin might have a 
protective effect on breast cancer especially for postmenopausal women with T2D.6 In contrast, short- 
term administration of metformin did not reduce the risk of developing breast cancer in diabetic 
women.5 Also, metformin did not show any significant advantage for any breast cancer patients who 
had recent-onset diabetes.21 Overall, these studies opened new possibilities for metformin to reduce 
and prevent the incidence, even for treating breast cancer in postmenopausal women with type II 
diabetes. 
METFORMIN SAFETY 
Biguanide, such as metformin, is widely used as first line oral drugs to regulate  
hyperinsulinemia and lower blood glucose in type II diabetic patients. It has been approved for clinical 
purpose since 1958 in United Kingdom and since 1995 in the United States.22 The mechanisms of 
metformin actions to regulate hyperglycaemia in T2D patients include lowering small intestinal 
glucose absorption, improving cellular glucose transport and uptake, decrease plasma insulin level,  
and increased insulin sensitivity.23 Metformin also reduce hepatic gluconeogenesis via activation of 
AMP-activated protein kinase or AMPK, which have an essential role in energy regulation in diabetes 
and other metabolic diseases.24 Subsequently, activation of AMPK by metformin might exerts an anti- 
tumour, anti-aging, cardiovascular, and neuroprotective effect in human.25 
Metformin is relatively cheap and safe for diabetes treatment. According to the United States 
Food and Drug Administration (FDA), there are several metformin-containing medicines approved for 
commercial use, including Glucophage and Glucovance.26 These drug are not associated with any 
hypoglycaemia events due to its pharmacokinetics, unless it is used with combination of other oral 
antidiabetic class or insulin injection.27 Yet, the use of metformin in the patient with severe renal 
impairment might be restricted, because there have been several incidences of lactic acidosis reported 
in patients treated with metformin (around 1.5% cases per 1000 patients per year). Other than that, 
minor side effects such as nausea, diarrhea, and gastritis might also occur during metformin 
administration.26,27 Earlier study has demonstrated that metformin used for diabetes patient is safe and 
well-tolerated for long term basis, at least for ten years.28 Metformin is also relatively safe not only for 
young adults but also for older people. Unfortunately, there is no data about the safety profile of this 
drug in very old people (more than 80 years old).29 
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METFORMIN ACTION IN BREAST CANCER 
The underlying mechanism of metformin action in cancer remains debatable. According to Rice 
et al. (2015), metformin might have dual effect in breast cancer. It could inhibit the cell growth 
directly, but also reduce oestradiol or estrogen production that have indirect impact to cell 
proliferation.30 
Firstly, as previously mentioned, metformin could lower gluconeogenesis in the liver by 
activation of AMPK via Liver Kinase B1 (LKB1) dependent mechanism. LKB1 is a tumour 
suppressor gene in epithelial tissues, and loss of its function is associated with a significant increase in 
lifetime risk of numerous epithelial cancer, including breast cancer.31 Zakikhani et al. (2006) observed 
that metformin could act as a growth inhibitor for epithelial cells, particularly for MCF-7 cells in  
breast cancer. They also demonstrated that AMPK activation by metformin is a hurdle for the 
antiproliferative effect of the drug by using small interfering RNA (siRNA).32 These finding suggested 
that metformin have a direct action as an activator of the LKB1/AMP kinase signalling pathway to 
suppress breast cancer cells. In addition, another study was demonstrated that metformin also could 
inhibit protein translation initiation and be able to reduce 30 to 40% protein synthesis in MCF-7 breast 
cancer. It caused a dose-dependent decrease in cap-dependent translation. The effect  on translation 
was associated with mammalian target of rapamycin (mTOR) inhibition, which is mediated  by 
AMPK, consequently lowering phosphorylation of S6 kinase and eIF4E-binding protein.33 This 
observation implicated that activation of AMPK lead to mTOR inhibition and result in the inhibition  
of breast cancer cells growth. 
Secondly, another suggested role of metformin in breast cancer is as an aromatase inhibitor. 
Estrogen inhibition also might play indirect role for reducing breast cancer growth. In rodent model of 
postmenopausal breast cancer, Giles et al. (2018) found out that metformin is capable of lowering the 
expression of local stromal aromatase (Figure 2), leading to reduction of estrogen production and 
estrogen receptor activation in the cells. Besides, they also showed that metformin could reduce the 
expression of CD68+ macrophages, an aromatase-positive macrophage which is responsible for 
aromatase production.34 Similar to these findings, a study using human endometrial cell as sample also 
showed that metformin attenuate aromatase activity. It was worked by decrease  cAMP-induced 
mRNA expression for aromatase in endometriotic stromal cells (ESCs).35 In summary, these 
observations suggest that metformin might be highly effective to inhibit the growth of cells via 
aromatase signalling pathway related to estrogen production. 
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Figure 2. Higher expression of local stromal aromatase (yellow line) was observed in untreated 
breast cancer mice compared to metformin group (brown line). Adapted from Giles et al. 
(2018).34 
Brown et al. (2009) introduced cAMP response element binding (CREB) protein, a compound 
that highly expressed in postmenopausal women with breast cancer. They observed that Inhibition of 
LKB1/AMPK signalling pathway in breast cancer, particularly in diabetic women, will cause de- 
phosphorylation of CREB regulated transcription co-activator 2 (CRTC2), which will result in 
activation of aromatase promoter named PII, and increase the production of estrogen in peripheral  
body tissue.36 Thus, higher activity of AMPK will give a negative effect for cancer cells. Moreover, 
recent observational study with human cells tissue has shown that metformin could decrease  
aromatase promoter PII activity via cytoplasmic retention of CRCT2. The inhibition of PII was a 
consequence of increase AMPK phosphorylation by higher LKB1 expression. So, CREB could not be 
activated, and cause the inhibition of aromatase stimulation.37 
All of the observation above might provide a better information about the dual use of metformin 
in breast cancer for future study. The direct and indirect mechanism of metformin to inhibit breast 
cancer growth are summarized in Figure 3. 
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Figure 3. Proposed metformin mechanism of action on AMPK with direct inhibition of cancer 
cells via mTOR and indirect inhibition via CREB/PII/aromatase signalling pathway.32,33,37 
CLINICAL TRIAL OF METFORMIN AS AROMATASE INHIBITOR 
Epidemiological studies heavily suggested that metformin is not only beneficial to prevent  
breast cancer but also clinically useful for preoperative and adjuvant therapy for the disease. Thus, 
many clinical studies are addressed to understand tumour biomarker involved in metformin and breast 
cancer cells interaction, whether it is a direct or indirect effect. 
Moreover, animal studies suggested that there are in vitro inhibition of aromatase in breast 
cancer cells by using metformin. In contrast with these findings, a study in human showed that there is 
no such trend was found for aromatase expression in tumour cells from a diabetic patient treated with 
metformin. They analysed the aromatase expression by collected tumour sample from breast cancer 
patient aged 48-77 years treated with metformin or another antidiabetic agent, followed by staining the 
cells with monoclonal aromatase antibody-677. Unfortunately, metformin did not provide lower 
aromatase expression in the patients compared to other treatment groups.38 But, that study was 
conducted in a small population which might interfere with the result. This finding might  also 
implicate that using metformin alone as an aromatase inhibitor will not provide a promising result. 
Combination therapy with aromatase inhibitors (AIs) drug line is also one of the main attractive 
options for breast cancer patient treatment. Recently, Zhao et al. (2017) conducted a clinical trial in 
post-menopausal women by using metformin with a combination of either exemestane 25 mg/d or 
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letrozole 2.5mg/d compared to these drugs alone. Again, this study also failed to show better 
improvement in small population patients with combination therapy compared to control group. In 
contrast, previous research about the combination of metformin with letrozole 2.5 mg/d to inhibit 
aromatase in Polycystic Ovarian Syndrome (PCOS) women were showing a positive effect of 
metformin as aromatase inhibitors.40 Several clinical trials are still on the run to answer the hypothesis 
from pre-clinical studies, for example, a clinical trial (NCT03192293) investigating the effect of 
combining metformin with fulvestrant (chemotherapy regiment). Hence, there is still an open window 
to make further observation, especially by combining metformin with other cancer agent in bigger 
population. 
CONCLUSION AND IMPLEMENTATION 
 
In conclusion, based on pre-clinical evidence, metformin appears to be beneficial as an adjuvant 
treatment to eradicate cancer, especially breast cancer. It has a dual effect in breast cancer including a 
direct impact by inhibiting mTOR signalling pathway and protein translation, or indirect impact by 
inhibiting CREB, aromatase activator for estrogen production. 
Considering metformin mechanism of action including pharmacokinetics, safety, and side effect 
has been explored, with extensive clinical use in type II diabetes patients around the world, the 
opportunity to study metformin for breast cancer treatment in the clinical trial setting is very 
captivating. Unfortunately, there are a lot of gaps to understand the benefit of metformin in treating 
cancer on human model diseases, especially breast cancer. Assessment for a cumulative duration of 
therapy and the cumulative dosage is necessary to answer the hesitance. The majority of the clinical 
trials aim to observe the treatment effect, while others evaluate metformin for prevention purpose. The 
result will be useful to define metformin future for breast cancer therapy option. 
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